RU95101840A - Сложные эфиры циклогексанола и содержащий их фармацевтический препарат - Google Patents

Сложные эфиры циклогексанола и содержащий их фармацевтический препарат

Info

Publication number
RU95101840A
RU95101840A RU95101840/04A RU95101840A RU95101840A RU 95101840 A RU95101840 A RU 95101840A RU 95101840/04 A RU95101840/04 A RU 95101840/04A RU 95101840 A RU95101840 A RU 95101840A RU 95101840 A RU95101840 A RU 95101840A
Authority
RU
Russia
Prior art keywords
esters
pharmaceutical agent
cyclohexanol
glucose
agent containing
Prior art date
Application number
RU95101840/04A
Other languages
English (en)
Other versions
RU2135465C1 (ru
Inventor
Хемерле Хорст
De]
Шуберт Герит
Белов Петер
Херлинг Андреас
Бургер Ханс-Йорг
Original Assignee
Хехст АГ (DE)
Хехст АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хехст АГ (DE), Хехст АГ filed Critical Хехст АГ (DE)
Publication of RU95101840A publication Critical patent/RU95101840A/ru
Application granted granted Critical
Publication of RU2135465C1 publication Critical patent/RU2135465C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Описываются сложные эфиры циклогексанола формулы, приведенной в описании и где остатки имеют указанные в описании значения. Соединения фармакологически эффективны и поэтому могут применяться в качестве лекарственного средства, в особенности для лечения диабета и других заболеваний, которые характеризуются повышенным выделением глюкозы печенью или повышенной активностью глюкозо-6-фосфотаза-системы.

Claims (1)

  1. Описываются сложные эфиры циклогексанола формулы, приведенной в описании и где остатки имеют указанные в описании значения. Соединения фармакологически эффективны и поэтому могут применяться в качестве лекарственного средства, в особенности для лечения диабета и других заболеваний, которые характеризуются повышенным выделением глюкозы печенью или повышенной активностью глюкозо-6-фосфотаза-системы.
RU95101840/04A 1994-02-16 1995-02-14 Сложные эфиры циклогексанола и содержащий их фармацевтический препарат RU2135465C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4404848.3 1994-02-16
DE4404848A DE4404848A1 (de) 1994-02-16 1994-02-16 Substituierte Cyclohexanolester, ihre Verwendung zur Behandlung von Krankheiten und pharmazeutische Präparate

Publications (2)

Publication Number Publication Date
RU95101840A true RU95101840A (ru) 1996-12-10
RU2135465C1 RU2135465C1 (ru) 1999-08-27

Family

ID=6510346

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95101840/04A RU2135465C1 (ru) 1994-02-16 1995-02-14 Сложные эфиры циклогексанола и содержащий их фармацевтический препарат

Country Status (21)

Country Link
US (3) US5567725A (ru)
EP (1) EP0672660B1 (ru)
JP (1) JPH07258220A (ru)
KR (1) KR100360128B1 (ru)
CN (1) CN1051298C (ru)
AT (1) ATE309222T1 (ru)
AU (1) AU679305B2 (ru)
CA (1) CA2142556A1 (ru)
CZ (1) CZ290065B6 (ru)
DE (2) DE4404848A1 (ru)
ES (1) ES2250966T3 (ru)
FI (1) FI950649A (ru)
HU (1) HUT73631A (ru)
IL (1) IL112655A (ru)
NO (1) NO305754B1 (ru)
NZ (1) NZ270490A (ru)
PL (1) PL178970B1 (ru)
RU (1) RU2135465C1 (ru)
SG (1) SG46690A1 (ru)
TW (1) TW295578B (ru)
ZA (1) ZA951220B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2333412T3 (es) * 2001-05-25 2010-02-22 Bristol-Myers Squibb Company Derivados de hidantoina como inhibidores de metaloproteinasas de matriz.
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
MX2015007433A (es) 2012-12-20 2015-12-07 Inception 2 Inc Compuestos de triazolona y usos de los mismos.
WO2015035059A1 (en) 2013-09-06 2015-03-12 Inception 2, Inc. Triazolone compounds and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4202184A1 (de) * 1992-01-28 1993-07-29 Hoechst Ag Substituierte salicylaldehyde zur behandlung von krankheiten
TW255880B (ru) * 1992-09-09 1995-09-01 Hoechst Ag
TW399041B (en) * 1992-09-09 2000-07-21 Hoechst Ag Substituted cyclohexane derivatives, the preparation and the use for treating diseases

Also Published As

Publication number Publication date
IL112655A0 (en) 1995-05-26
CN1126198A (zh) 1996-07-10
NO950564D0 (no) 1995-02-15
ATE309222T1 (de) 2005-11-15
NO950564L (no) 1995-08-17
AU1225595A (en) 1995-08-24
KR950032136A (ko) 1995-12-20
CN1051298C (zh) 2000-04-12
EP0672660B1 (de) 2005-11-09
SG46690A1 (en) 1998-02-20
FI950649A (fi) 1995-08-17
DE59511025D1 (de) 2005-12-15
CZ37995A3 (en) 1995-09-13
TW295578B (ru) 1997-01-11
US5629311A (en) 1997-05-13
PL178970B1 (pl) 2000-07-31
PL307284A1 (en) 1995-08-21
US5567725A (en) 1996-10-22
HUT73631A (en) 1996-08-28
IL112655A (en) 2003-05-29
CA2142556A1 (en) 1995-08-17
NO305754B1 (no) 1999-07-19
US5719170A (en) 1998-02-17
EP0672660A2 (de) 1995-09-20
RU2135465C1 (ru) 1999-08-27
NZ270490A (en) 1996-02-27
ES2250966T3 (es) 2006-04-16
DE4404848A1 (de) 1995-08-17
CZ290065B6 (cs) 2002-05-15
FI950649A0 (fi) 1995-02-14
ZA951220B (en) 1995-10-11
KR100360128B1 (ko) 2003-04-26
HU9500456D0 (en) 1995-03-28
AU679305B2 (en) 1997-06-26
EP0672660A3 (de) 1997-05-28
JPH07258220A (ja) 1995-10-09

Similar Documents

Publication Publication Date Title
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
GB2303629B (en) Hydroxamic acids and their use as metalloproteinase inhibitors
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
RU95110109A (ru) Комплекс, содержащий аналог человеческого инсулина, и фармацевтическая композиция на его основе
DE69433818D1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
DE69815122D1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
FR2635265B1 (fr) Composition pharmaceutique intraveineuse comprenant de la cyclosporine en tant que principe actif et procede pour sa preparation
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
RU94038043A (ru) Применение замещенных производных аденина для лечения множественного склероза
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
DE69433723D1 (de) Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
BG101118A (en) Therapeutical compounds
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
RU93045145A (ru) Замещенные производные циклогексана и их применение для лечения заболеваний, содержащее их лекарственное средство
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
AU7425391A (en) Use of n-alkylated 1, 4-dihydropyridinedicarboxylic acid esters as medicaments, new compounds and processes for their preparation
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
ATE157871T1 (de) Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind
RU95101840A (ru) Сложные эфиры циклогексанола и содержащий их фармацевтический препарат
RU94000064A (ru) Новые 2-циано-3-гидроксипропенамиды, метод их получения и содержащие их фармацевтические композиции
FI964918A0 (fi) Lääkeainesuoloja
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
EA200401295A1 (ru) Статиновая терапия для усиления поддержания когнитивной функции

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20040215